## Wing Leung

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3830580/publications.pdf

Version: 2024-02-01

124 papers 8,036 citations

43 h-index 86 g-index

127 all docs

127 docs citations

127 times ranked

8603 citing authors

#	Article	IF	CITATIONS
1	Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation. New England Journal of Medicine, 2009, 360, 2730-2741.	27.0	1,059
2	NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia. Journal of Clinical Oncology, 2010, 28, 955-959.	1.6	563
3	Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncology, The, 2010, 11, 543-552.	10.7	514
4	Extended Follow-up of Long-Term Survivors of Childhood Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2003, 349, 640-649.	27.0	415
5	Determinants of Antileukemia Effects of Allogeneic NK Cells. Journal of Immunology, 2004, 172, 644-650.	0.8	397
6	Late Effects of Treatment in Survivors of Childhood Acute Myeloid Leukemia. Journal of Clinical Oncology, 2000, 18, 3273-3279.	1.6	213
7	Cidofovir for the Treatment of Adenoviral Infection in Pediatric Hematopoietic Stem Cell Transplant Patients. Transplantation, 2006, 81, 1398-1404.	1.0	198
8	Comparative Analysis of Different Approaches to Measure Treatment Response in Acute Myeloid Leukemia. Journal of Clinical Oncology, 2012, 30, 3625-3632.	1.6	188
9	Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood, 2012, 120, 468-472.	1.4	176
10	High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood, 2011, 118, 223-230.	1.4	157
11	A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. Cytotherapy, 2012, 14, 830-840.	0.7	149
12	Comparison of Killer Ig-Like Receptor Genotyping and Phenotyping for Selection of Allogeneic Blood Stem Cell Donors. Journal of Immunology, 2005, 174, 6540-6545.	0.8	148
13	Long-Term Outcome and Evaluation of Organ Function in Pediatric Patients Undergoing Haploidentical and Matched Related Hematopoietic Cell Transplantation for Sickle Cell Disease. Biology of Blood and Marrow Transplantation, 2013, 19, 820-830.	2.0	127
14	Tâ€cell alloreactivity dominates natural killer cell alloreactivity in minimally Tâ€cellâ€depleted HLAâ€nonâ€identical paediatric bone marrow transplantation. British Journal of Haematology, 2003, 123, 323-326.	2.5	124
15	Improved Prognosis for Older Adolescents With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2011, 29, 386-391.	1.6	122
16	A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma. Clinical Cancer Research, 2017, 23, 6441-6449.	7.0	116
17	Use of NK cell activity in cure by transplant. British Journal of Haematology, 2011, 155, 14-29.	2.5	110
18	Timeline, Epidemiology, and Risk Factors for Bacterial, Fungal, and Viral Infections in Children and Adolescents after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 94-101.	2.0	110

#	Article	IF	Citations
19	Phase I Study of Vandetanib During and After Radiotherapy in Children With Diffuse Intrinsic Pontine Glioma. Journal of Clinical Oncology, 2010, 28, 4762-4768.	1.6	108
20	A Prospective Cohort Study of Late Sequelae of Pediatric Allogeneic Hematopoietic Stem Cell Transplantation. Medicine (United States), 2007, 86, 215-224.	1.0	104
21	Treatment Outcomes in Black and White Children With Cancer: Results From the SEER Database and St Jude Children's Research Hospital, 1992 Through 2007. Journal of Clinical Oncology, 2012, 30, 2005-2012.	1.6	104
22	Significant functional heterogeneity among KIR2DL1 alleles and a pivotal role of arginine245. Blood, 2009, 114, 5182-5190.	1.4	100
23	Gamma Delta T Cell Reconstitution Is Associated with Fewer Infections and Improved Event-Free Survival after Hematopoietic Stem Cell Transplantation for Pediatric Leukemia. Biology of Blood and Marrow Transplantation, 2015, 21, 130-136.	2.0	92
24	Outcomes of Growth Hormone Replacement Therapy in Survivors of Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2002, 20, 2959-2964.	1.6	90
25	Infusions of Allogeneic Natural Killer Cells as Cancer Therapy. Clinical Cancer Research, 2014, 20, 3390-3400.	7.0	86
26	Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation. British Journal of Haematology, 2013, 162, 147-161.	2.5	80
27	A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia., 2019, 7, 81.		74
28	Prediction of T-cell reconstitution by assessment of T-cell receptor excision circle before allogeneic hematopoietic stem cell transplantation in pediatric patients. Blood, 2005, 105, 886-893.	1.4	73
29	Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells. Clinical Cancer Research, 2017, 23, 5824-5835.	7.0	67
30	TOX2 regulates human natural killer cell development by controlling T-BET expression. Blood, 2014, 124, 3905-3913.	1.4	66
31	KIR–HLA receptorâ€igand mismatch associated with a graftâ€versusâ€tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors. Pediatric Blood and Cancer, 2009, 53, 120-124.	1.5	64
32	Phase I and Clinical Pharmacology Study of Bevacizumab, Sorafenib, and Low-Dose Cyclophosphamide in Children and Young Adults with Refractory/Recurrent Solid Tumors. Clinical Cancer Research, 2013, 19, 236-246.	7.0	64
33	Multiplex and Genome-Wide Analyses Reveal Distinctive Properties of KIR+ and CD56+ T Cells in Human Blood. Journal of Immunology, 2013, 191, 1625-1636.	0.8	62
34	Second malignancy after treatment of childhood non-Hodgkin lymphoma. Cancer, 2001, 92, 1959-1966.	4.1	59
35	Effect of Donor KIR2DL1 Allelic Polymorphism on the Outcome of Pediatric Allogeneic Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology, 2013, 31, 3782-3790.	1.6	57
36	Cognitive Outcome After Pediatric Stem-Cell Transplantation: Impact of Age and Total-Body Irradiation. Journal of Clinical Oncology, 2014, 32, 3982-3988.	1.6	54

#	Article	IF	CITATIONS
37	Pulmonary dysfunction in survivors of childhood hematologic malignancies after allogeneic hematopoietic stem cell transplantation. Cancer, 2010, 116, 2020-2030.	4.1	53
38	Longitudinal Changes in Body Mass and Composition in Survivors of Childhood Hematologic Malignancies After Allogeneic Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology, 2012, 30, 3991-3997.	1.6	52
39	Modulation of NKG2D ligand expression and metastasis in tumors by spironolactone via RXRÎ <sup>3</sup> activation. Journal of Experimental Medicine, 2013, 210, 2675-2692.	8.5	52
40	Outcome of hematopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome. Pediatric Blood and Cancer, 2006, 47, 931-935.	1.5	51
41	A Distinct Subset of Highly Proliferative and Lentiviral Vector (LV)-Transducible NK Cells Define a Readily Engineered Subset for Adoptive Cellular Therapy. Frontiers in Immunology, 2019, 10, 2001.	4.8	51
42	Human CD34+ cell preparations contain over 100-fold greater NOD/SCID mouse engrafting capacity than do CD34â° cell preparations. Experimental Hematology, 2001, 29, 910-921.	0.4	49
43	Combination Immunotherapy with Clinical-Scale Enriched Human $\hat{I}^3\hat{I}$ T cells, hu14.18 Antibody, and the Immunocytokine Fc-IL7 in Disseminated Neuroblastoma. Clinical Cancer Research, 2005, 11, 8486-8491.	7.0	47
44	Total and Active Rabbit Antithymocyte Globulin (rATG;Thymoglobulin®) Pharmacokinetics in Pediatric Patients Undergoing Unrelated Donor Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 274-278.	2.0	47
45	Haploidentical stem cell transplantation augmented by CD45RA negative lymphocytes provides rapid engraftment and excellent tolerability. Pediatric Blood and Cancer, 2015, 62, 666-673.	1.5	46
46	Selective Tâ€cell depletion targeting <scp>CD</scp> 45 <scp>RA</scp> reduces viremia and enhances early Tâ€cell recovery compared with <scp>CD</scp> 3â€targeted Tâ€cell depletion. Transplant Infectious Disease, 2018, 20, e12823.	1.7	46
47	Impact of immune modulation with in vivo T-cell depletion and myleoablative total body irradiation conditioning on outcomes after unrelated donor transplantation for childhood acute lymphoblastic leukemia. Blood, 2012, 119, 6155-6161.	1.4	40
48	Natural killer cell therapy in children with relapsed leukemia. Pediatric Blood and Cancer, 2015, 62, 1468-1472.	1.5	39
49	Ex VivoCulture of Cord Blood CD34+Cells Expands Progenitor Cell Numbers, Preserves Engraftment Capacity in Nonobese Diabetic/Severe Combined Immunodeficient Mice, and Enhances Retroviral Transduction Efficiency. Human Gene Therapy, 1999, 10, 2927-2940.	2.7	38
50	Longitudinal analysis of antibody response to immunization in paediatric survivors after allogeneic haematopoietic stem cell transplantation. British Journal of Haematology, 2012, 156, 109-117.	2.5	37
51	Prospective Detection of Respiratory Pathogens in Symptomatic Children With Cancer. Pediatric Infectious Disease Journal, 2013, 32, e99-e104.	2.0	37
52	Diagnostic Yield of Bronchoalveolar Lavage Is Low in Allogeneic Hematopoietic Stem Cell Recipients Receiving Immunosuppressive Therapy or with Acute Graft-versus-Host Disease: The St. Jude Experience, 1990-2002. Biology of Blood and Marrow Transplantation, 2007, 13, 831-837.	2.0	36
53	NK Cell Genotype and Phenotype at Diagnosis of Acute Lymphoblastic Leukemia Correlate with Postinduction Residual Disease. Clinical Cancer Research, 2014, 20, 5986-5994.	<b>7.</b> O	36
54	Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony–Stimulating Factor, Interleukin-2, and Haploidentical Natural Killer Cells. Biology of Blood and Marrow Transplantation, 2017, 23, 1910-1917.	2.0	35

#	Article	IF	CITATIONS
55	Quantity and quality of engrafting cells in cord blood and autologous mobilized peripheral blood. Biology of Blood and Marrow Transplantation, 1999, 5, 69-76.	2.0	34
56	Prophylaxis ofPneumocystis carinii pneumonia with atovaquone in children with leukemia. Cancer, 2007, 109, 1654-1658.	4.1	33
57	Antibody-Dependent Cell-Mediated Cytotoxicity Overcomes NK Cell Resistance in <1>MLL 1 -Rearranged Leukemia Expressing Inhibitory KIR Ligands but Not Activating Ligands. Clinical Cancer Research, 2012, 18, 6296-6305.	7.0	33
58	Etiology and Outcome of Graft Failure in Pediatric Hematopoietic Stem Cell Transplant Recipients. Journal of Pediatric Hematology/Oncology, 2003, 25, 955-959.	0.6	32
59	Phenotype and function of human natural killer cells purified by using a clinical-scale immunomagnetic method. Cancer Immunology, Immunotherapy, 2005, 54, 389-394.	4.2	32
60	Iron overload in survivors of childhood leukemia after allogeneic hematopoietic stem cell transplantation. Pediatric Transplantation, 2009, 13, 348-352.	1.0	31
61	Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy. British Journal of Haematology, 2015, 168, 94-101.	2.5	31
62	Improved survival rate in T-cell depleted haploidentical hematopoietic cell transplantation over the last 15 years at a single institution. Bone Marrow Transplantation, 2020, 55, 929-938.	2.4	31
63	Human ???? T Cells From G-CSF-Mobilized Donors Retain Strong Tumoricidal Activity and Produce Immunomodulatory Cytokines After Clinical-Scale Isolation. Journal of Immunotherapy, 2005, 28, 73-78.	2.4	30
64	Molecular determinant-based typing of KIR alleles and KIR ligands. Clinical Immunology, 2011, 138, 274-281.	3.2	25
65	<i>Ex Vivo</i> Activation of CD56+ Immune Cells That Eradicate Neuroblastoma. Cancer Research, 2013, 73, 2608-2618.	0.9	25
66	Clinical Utility of Computed Tomography Screening of Chest, Abdomen, and Sinuses before Hematopoietic Stem Cell Transplantation: The St. Jude Experience. Biology of Blood and Marrow Transplantation, 2009, 15, 490-495.	2.0	24
67	Rapid production of clinicalâ€grade SARSâ€CoVâ€2 specific T cells. Advances in Cell and Gene Therapy, 2020, 3, e101.	0.9	24
68	Blood Dendritic Cells Suppress NK Cell Function and Increase the Risk of Leukemia Relapse after Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 598-607.	2.0	23
69	Impact of Adenoviral Stool Load on Adenoviremia in Pediatric Hematopoietic Stem Cell Transplant Recipients. Pediatric Infectious Disease Journal, 2015, 34, 562-565.	2.0	22
70	KIR-incompatible hematopoietic-cell transplantation for poor prognosis infant acute lymphoblastic leukemia. Blood, 2006, 107, 1238-1239.	1.4	21
71	Phase I Study of the Tolerability and Pharmacokinetics of Palifermin in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 1309-1314.	2.0	21
72	A human-murine chimera model for in utero human hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation, 1999, 5, 1-7.	2.0	20

#	Article	IF	Citations
73	Allogeneic graft-versus-hepatoblastoma effect. Pediatric Blood and Cancer, 2006, 46, 501-505.	1.5	20
74	A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation. Blood, 2021, 137, 983-993.	1.4	20
75	Cyclooxygenase-2 Inhibition to Treat Radiation-Induced Brain Necrosis and Edema. Journal of Pediatric Hematology/Oncology, 2004, 26, 253-255.	0.6	19
76	Deficient innate immunity, thymopoiesis, and gene expression response to radiation in survivors of childhood acute lymphoblastic leukemia. Cancer Epidemiology, 2010, 34, 303-308.	1.9	19
77	Pre–Hematopoietic Stem Cell Transplant Lung Function and Pulmonary Complications in Children. Annals of the American Thoracic Society, 2014, 11, 1576-1585.	3.2	18
78	Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium. Biology of Blood and Marrow Transplantation, 2018, 24, 1651-1656.	2.0	18
79	Caregiver and health care provider preferences of nutritional support in a hematopoietic stem cell transplant unit. Pediatric Blood and Cancer, 2015, 62, 1473-1476.	1.5	17
80	PRL-3 Mediates the Protein Maturation of ULBP2 by Regulating the Tyrosine Phosphorylation of HSP60. Journal of Immunology, 2015, 194, 2930-2941.	0.8	17
81	Human Hematopoietic Stem/Progenitor Cells Generate CD5 <sup>+</sup> B Lymphoid Cells in NOD/SCID Mice. Stem Cells, 1999, 17, 242-252.	3.2	16
82	Combination chemotherapy with clofarabine, cyclophosphamide, and etoposide in children with refractory or relapsed haematological malignancies. British Journal of Haematology, 2012, 156, 275-279.	2.5	16
83	Detection of respiratory viruses in asymptomatic children undergoing allogeneic hematopoietic cell transplantation. Pediatric Blood and Cancer, 2013, 60, 149-151.	1.5	16
84	Genome-wide single-nucleotide polymorphism analysis revealed SUFU suppression of acute graft-versus-host disease through downregulation of HLA-DR expression in recipient dendritic cells. Scientific Reports, 2015, 5, 11098.	3.3	16
85	Prediction of CD34 + cell yield in hematopoietic cell products from children by peripheral blood CD34 + cell counts. Cytotherapy, 2012, 14, 473-482.	0.7	15
86	COMPARISONS OF ALLOREACTIVE POTENTIAL OF CLINICAL HEMATOPOIETIC GRAFTS1. Transplantation, 1999, 68, 628-635.	1.0	15
87	Prospective evaluation for respiratory pathogens in children with sickle cell disease and acute respiratory illness. Pediatric Blood and Cancer, 2014, 61, 507-511.	1.5	14
88	Possible Allogeneic Graft-Versus-Tumor Effect in Childhood Melanoma. Journal of Pediatric Hematology/Oncology, 2003, 25, 982-986.	0.6	13
89	KIR2DL2/2DL3-E35 alleles are functionally stronger than -Q35 alleles. Scientific Reports, 2016, 6, 23689.	3.3	13
90	Escalation to High-Dose Defibrotide in Patients with Hepatic Veno-Occlusive Disease. Biology of Blood and Marrow Transplantation, 2015, 21, 2148-2153.	2.0	11

#	Article	IF	CITATIONS
91	Favorable preliminary results using TLI/ATGâ€based immunomodulatory conditioning for matched unrelated donor allogeneic hematopoietic stem cell transplantation in pediatric severe aplastic anemia. Pediatric Transplantation, 2011, 15, 628-634.	1.0	10
92	Treatment of Hepatoblastoma With High-dose Chemotherapy and Stem Cell Rescue. Journal of Pediatric Hematology/Oncology, 2014, 36, 362-368.	0.6	10
93	Phase I Study of the Safety and Pharmacokinetics of Plerixafor in Children Undergoing a Second Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Leukemia. Biology of Blood and Marrow Transplantation, 2014, 20, 1224-1228.	2.0	10
94	Immunotherapy in Acute Leukemia. Seminars in Hematology, 2009, 46, 89-99.	3.4	9
95	SVSI: Fast and Powerful Setâ€Valued System Identification Approach to Identifying Rare Variants in Sequencing Studies for Ordered Categorical Traits. Annals of Human Genetics, 2015, 79, 294-309.	0.8	9
96	Donor lymphocyte infusion and methotrexate for immune recovery after Tâ€cell depleted haploidentical transplantation. American Journal of Hematology, 2018, 93, 169-178.	4.1	9
97	Longâ€term results of the <scp>NFâ€08â€TM</scp> protocol in stem cell transplant for patients with thalassemia major: A multiâ€center largeâ€sample study. American Journal of Hematology, 2020, 95, E297-E299.	4.1	9
98	Selection of Stem Cells by Using Antibodies That Target Different CD34 Epitopes Yields Different Patterns of T-Cell Differentiation. Stem Cells, 2007, 25, 537-542.	3.2	8
99	A Phase 2 Trial of KIR-Mismatched Unrelated Donor Transplantation Using in Vivo T Cell Depletion with Antithymocyte Globulin in Acute Myelogenous Leukemia: Children's Oncology Group AAML05P1 Study. Biology of Blood and Marrow Transplantation, 2020, 26, 712-717.	2.0	8
100	EBV lymphoproliferative disease of host origin after haploidentical stem cell transplantation. Pediatric Blood and Cancer, 2007, 49, 869-872.	1.5	7
101	Effects of Conditioning Regimens and T Cell Depletion in Hematopoietic Cell Transplantation for Primary Immune Deficiency. Biology of Blood and Marrow Transplantation, 2012, 18, 1911-1920.	2.0	7
102	Successful Allogeneic Hematopoietic Cell Engraftment after a Minimal Conditioning Regimen in Children with Relapsed or Refractory Solid Tumors. Biology of Blood and Marrow Transplantation, 2013, 19, 291-297.	2.0	7
103	Outcomes of allogeneic transplantation for hemoglobin Bart's hydrops fetalis syndrome in Hong Kong. Pediatric Transplantation, 2021, 25, e14037.	1.0	7
104	Neuroendocrine Complications of Cancer Therapy. , 2005, , 51-80.		5
105	Diagnostic Challenge in Recurrent Skin Rash After Autologous Bone Marrow Transplantation. Journal of Pediatric Hematology/Oncology, 2006, 28, 525-528.	0.6	5
106	Routine Pre- and Post-Hematopoietic Stem Cell Transplant Computed Tomography of the Abdomen for Detecting Invasive Fungal Infection Has Limited Value. Biology of Blood and Marrow Transplantation, 2015, 21, 1132-1135.	2.0	5
107	Comparing Administration of Nutrition Support With Prescribed Dose. Journal of Pediatric Oncology Nursing, 2011, 28, 273-286.	1.5	3
108	LONG-TERM COMPLETE REMISSION AND IMMUNE TOLERANCE AFTER INTENSIVE CHEMOTHERAPY FOR LYMPHOPROLIFERATIVE DISORDERS COMPLICATING LIVER TRANSPLANT1. Transplantation, 1999, 67, 1487-1489.	1.0	3

#	Article	IF	CITATIONS
109	Natural killer cell therapy for cancer: delivering on a promise. Transfusion, 2013, 53, 245-248.	1.6	2
110	An Improved Method With High Specificity for KIR2DL1 Functional Allele Typing. Laboratory Medicine, 2015, 46, 207-213.	1.2	2
111	Irradiationâ€free RIC HSCT has a tolerable safety profile and is effective therapy for pediatric bone marrow failure syndromes. Pediatric Transplantation, 2021, 25, e13855.	1.0	2
112	Expanded Natural Killer Cells for Cellular Therapy of Acute Myeloid Leukemia Blood, 2007, 110, 2743-2743.	1.4	2
113	Successful haploidentical hematopoietic stem cell transplantation (HSCT) and durable engraftment by repeated donor lymphocyte infusions for a Chinese patient with transfusionâ€dependent hemoglobin (Hb) Hammersmith and massive splenomegaly. Pediatric Transplantation, 2022, 26, e14278.	1.0	2
114	Successful engraftment determined by the quality rather than quantity of the haematopoietic graft: a lesson from coâ€transplantation of unrelated cord blood and mobilized haploidentical peripheral blood in monozygotic twins. British Journal of Haematology, 2017, 179, 677-679.	2.5	1
115	Allogeneic <scp>CD</scp> 27â€depleted cells in adoptive cell therapy. Advances in Cell and Gene Therapy, 2019, 2, e45.	0.9	1
116	Excellent Survival Outcomes of Pediatric Patients With Acute Myeloid Leukemia Treated With the MASPORE 2006 Protocol. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e290-e300.	0.4	1
117	Pulmonary Function in Pediatric survivors of non-Malignant Disorders after Allogeneic Hematopoietic Stem Cell Transplantation Blood, 2008, 112, 2136-2136.	1.4	1
118	Hematopoietic stem cell and natural killer cell transplantation. , 0, , 527-548.		0
119	A new set-valued system identification approach to identifying rare genetic variants for ordered categorical phenotype. BMC Bioinformatics, 2014, 15, .	2.6	0
120	Effectiveness of Bath Wipes After Hematopoietic Cell Transplantation: A Randomized Trial. Journal of Pediatric Oncology Nursing, 2020, 37, 390-397.	1.5	0
121	Longitudinal Analysis of Antibody Response to Immunization in Pediatric Survivors After Allogeneic Hematopoietic Stem Cell Transplantation Blood, 2009, 114, 795-795.	1.4	0
122	Longitudinal Analysis of Body Mass and Composition in Survivors of Pediatric Hematological Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2011, 118, 1991-1991.	1.4	0
123	Transplant Outcome of Pediatric and Young Adult Patients with Aplastic Anemia: St Jude Children's Research Hospital Experience. Blood, 2014, 124, 1210-1210.	1.4	0
124	Depletion of CD45RA+ Cells from Mobilized Peripheral Blood Stem Cell (PBSC) Collections As an Integral Part of Hematopoietic Stem Cell Transplantation (HSCT) and Cellular Therapy (CT). Blood, 2014, 124, 1130-1130.	1.4	0